| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PXS Stock Overview
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide.
Provexis plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0074 |
| 52 Week High | UK£0.011 |
| 52 Week Low | UK£0.0065 |
| Beta | 1.51 |
| 1 Month Change | -1.33% |
| 3 Month Change | -26.00% |
| 1 Year Change | -9.76% |
| 3 Year Change | 127.69% |
| 5 Year Change | 45.10% |
| Change since IPO | -88.30% |
Recent News & Updates
We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
We're Not Worried About Provexis' (LON:PXS) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Shareholder Returns
| PXS | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | 2.1% | -4.3% | 0.03% |
| 1Y | -9.8% | -5.5% | -8.3% |
Return vs Industry: PXS underperformed the UK Personal Products industry which returned -6.8% over the past year.
Return vs Market: PXS matched the UK Market which returned -9% over the past year.
Price Volatility
| PXS volatility | |
|---|---|
| PXS Average Weekly Movement | 9.9% |
| Personal Products Industry Average Movement | 7.9% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PXS is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PXS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2 | Ian Ford | https://www.provexis.com |
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company’s syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats.
Provexis plc Fundamentals Summary
| PXS fundamental statistics | |
|---|---|
| Market Cap | UK£16.41m |
| Earnings (TTM) | -UK£283.34k |
| Revenue (TTM) | UK£479.45k |
35.2x
P/S Ratio-61.7x
P/E RatioIs PXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXS income statement (TTM) | |
|---|---|
| Revenue | UK£479.45k |
| Cost of Revenue | UK£52.70k |
| Gross Profit | UK£426.76k |
| Other Expenses | UK£710.09k |
| Earnings | -UK£283.34k |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00012 |
| Gross Margin | 89.01% |
| Net Profit Margin | -59.10% |
| Debt/Equity Ratio | 0.0% |
How did PXS perform over the long term?
See historical performance and comparison